RT Journal Article
SR Electronic
T1 Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.23.20137620
DO 10.1101/2020.06.23.20137620
A1 Mina Psichogiou
A1 Andreas Karabinis
A1 Ioanna D. Pavlopoulou
A1 Dimitrios Basoulis
A1 Konstantinos Petsios
A1 Sotirios Roussos
A1 Maria Patrikaki
A1 Edison Jahaj
A1 Konstantinos Protopapas
A1 Konstantinos Leontis
A1 Vasiliki Rapti
A1 Anastasia Kotanidou
A1 Anastasia Antoniadou
A1 Garyphallia Poulakou
A1 Dimitrios Paraskevis
A1 Vana Sypsa
A1 Angelos Hatzakis
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.23.20137620.abstract
AB Greece is a country with limited spread of SARS-CoV-2 and cumulative infection attack rate of 0.12% (95%CI 0.06%-0.26%). Health care workers (HCWs) are a well-recognized risk group for COVID-19. The study aimed to estimate the seroprevalence of antibodies to SARS-CoV-2 in two hospitals and assess potential risk factors. Hospital-1 was involved in the care of COVID-19 patients while hospital-2 was not. A validated, rapid, IgM/IgG antibody point-of care test was used. 1,495 individuals consented to participate (response rate 77%). The anti-SARS-CoV-2 weighted prevalence was 1.07% (95%CI 0.37-1.78) overall and 0.44% (95%CI 0.12-1.13) and 2.4% (95%CI 0.51-8.19) in hospital-1 and hospital-2, respectively. The overall, hospital-1, and hospital-2 seroprevalence was 9, 3 and 20 times higher than the estimated infection attack rate in general population, respectively. Suboptimal use of personal protective equipment was noted in both hospitals. These data have implications for the preparedness of a second wave of COVID-19 epidemic.Competing Interest StatementThe study was funded by research grant from Gilead SciencesFunding StatementThe study was funded by research grant from Gilead SciencesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics and Scientific Boards of Laiko General Hospital, Athens, Greece and the Onassis Cardiac Surgery Center, Athens, GreeceAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available at the Pergamos database of the National and Kapodistrian University of Athens, upon acceptance of the article by a journal